Podcast Episodes
Back to Search
Abivax CEO Marc de Garidel discusses Obefazimod's phase 3 trial result in ulcerative colitis, and what is next for the company
He covers the mechanism of action, this week's efficacy and safety data, what it might mean for the maintenance trial that will read out in 2Q26, add…
1 year, 1 month ago
AI x Bio Summit: Recursion's Chief R&D Officer & CCO Najat Khan describes how the company leverages AI - including in both the dry lab and the wet lab, and all through clinical trials
She describes Recursion's work, and what the acquisition of Exscientia has brought to the company. Plus, how AI can not only help with drug design, b…
1 year, 1 month ago
After receiving a CRL for its RP1 oncolytic immunotherapy yesterday, the CEO of Replimune walks us through the program's timeline and history, and what this might mean for its future
CEO Sushil Patel walks us through the decisions behind the design of the IGNYTE phase 1/2 study and the ongoing IGNYTE-3 study, he gives Replimune's …
1 year, 1 month ago
AI x Bio Summit: The CEO of Alto Neuroscience, which is working on precision medicine for neuroscience, talks about how the company is using AI and machine learning in its development programs
Amit Etkin says Alto Neuro is trying to use machine learning to understand signals from the complexity of the brain, and the company is also embeddin…
1 year, 1 month ago
NYSE Strategist Eric Criscuolo shares his take on the markets and biotech sentiment
He discusses the importance of interest rates to high risk sectors like biotech, and comment on how our sector has not performed lately like other "r…
1 year, 1 month ago
AI x Bio Summit: The Co-Founder and Head of Machine Learning at Dyno Therapeutics describes how his company is using AI to design better capsids
Sam Sinai talks about how capsids are being more precisely designed today, which is allowing drug developers to better target them to different organ…
1 year, 1 month ago
RBC's Healthcare Desk Strategist Chris McCarthy discusses biotech sentiment, and positioning around key events and catalysts that are upcoming
He highlights recent M&A, but also notes how the sector has not been reliant on deals like it has in the past. Plus, discussing how Sarepta's wild ri…
1 year, 1 month ago
AI x Bio Summit: Nimbus Therapeutics' new CEO and head of R&D describe how AI is an isn't used in the company's R&D process
CEO Abbas Kazimi and President of R&D Peter Tummino discuss how AI integrates into their discovery and clinical development work, and walk us through…
1 year, 1 month ago
Metsera CEO Whit Bernard shares an update on the company's obesity programs, and comments on the state of the field post ADA
He describes data that Mestera presented at ADA for its monthly-dosed GLP1 and also its amylin analog. Plus, recent learnings about the field in gene…
1 year, 1 month ago
Cambridge, MA based Avalyn Pharma is developing a novel inhaled formulation of pirfenidone and other medicines for pulmonary fibrosis - it just raised a $100M (up round) series D financing
CEO Lyn Baranowski describes the therapy and demonstrates the nebulizer that delivers it, and explains how Avalyn's method is designed increase the d…
1 year, 1 month ago